NASDAQ : ARDX
Ardelyx, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 755.04M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 755.04M |
| Enterprise Value | 755.72M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 249.19M |
| Shares Outstanding | 249.19M |
| Shares Change (YoY) | +2.91% |
| Shares Change (QoQ) | +0.90% |
| Owned by Insiders (%) | 3.38% |
| Owned by Institutions (%) | 60.48% |
| Float | 210.66M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 110.18 |
| PS Ratio | 1.67 |
| Forward PS | 1.43 |
| PB Ratio | 5.07 |
| P/TBV Ratio | 5.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.34 |
| Quick Ratio | 2.89 |
| Debt / Equity | 1.90 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.24 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -38.61% |
| Return on Assets (ROA) | -4.25% |
| Return on Invested Capital (ROIC) | -24.09% |
| Return on Capital Employed (ROCE) | -7.99% |
| Weighted Average Cost of Capital (WACC) | 8.36% |
| Revenue Per Employee | $922,074 |
| Profits Per Employee | -$113,910 |
| Employee Count | 489 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 4.68 |
Taxes
| Measure | Value |
|---|
| Income Tax | 227,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -38.91% |
| 50-Day Moving Average | 3.43 |
| 200-Day Moving Average | 5.34 |
| Relative Strength Index (RSI) | 37.29 |
| Average Volume (20 Days) | 4,408,725 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 30.24M |
| Short Previous Month | 27.68M |
| Short % of Shares Out | 12.13% |
| Short % of Float | 14.35% |
| Short Ratio (days to cover) | 6.65 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 450.89M |
| Gross Profit | 338.28M |
| Operating Income | -35.45M |
| Pretax Income | -55.48M |
| Net Income | -55.70M |
| EBITDA | -32.11M |
| EBIT | -35.45M |
| Loss Per Share | -$0.23 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 281.83M |
| Total Debt | 282.51M |
| Net Cash | -677,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 149.01M |
| Book Value Per Share | 0.60 |
| Working Capital | 309.71M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -17.32M |
| Capital Expenditures | -599,000 |
| Depreciation & Amortization | 3.35M |
| Net Borrowing | 48.04M |
| Free Cash Flow | -17.92M |
| FCF Per Share | -$0.07 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.02% |
| Operating Margin | -7.86% |
| Pretax Margin | -12.30% |
| Profit Margin | -12.35% |
| EBITDA Margin | -7.12% |
| EBIT Margin | -7.86% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.91% |
| Shareholder Yield | n/a |
| Earnings Yield | -7.51% |
| FCF Yield | -2.37% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.80 |
| Price Target Difference | 322.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 27.00% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.82 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |